随着时间的推移，生长抑素类似物（SSA）在患有神经内分泌肿瘤（NET）的患者中的具体适应证逐渐形成。本综述的目的是总结和讨论与长效SSA在NET中最相关的数据。进行了一项叙述性综述，包括关注与NET患者中的长效奥曲肽、兰雷肽和帕西瑞肽治疗有关的出版物。长效SSA在NET患者中得到了行之有效且广泛使用的证实。长效奥曲肽和兰雷肽与短效制剂相比具有相同的安全性，同时患者的依从性和遵循性进一步得到改善。在过去的20年中，除了一些随机第3期试验外，还进行了许多回顾性和前瞻性研究，这些研究揭示了对进展无疾病生存期的不同但实质性影响，不仅在胃肠胰NET中，还在肺部和来源不明的NET中。对SSA的最常见肿瘤反应是稳定疾病，但可以观察到客观反应，更常见于高剂量方案和MEN1相关的胰腺NET患者。肿瘤负担低、肿瘤分级低（G1和低G2）、良好的病情状态和作为一线治疗的使用是NET患者对SSA的主要预测因素。帕西瑞肽在少数研究中进行了评估。该化合物仍然是一种有前途的SSA，并且有望进一步评估其作为NET治疗中的潜在额外适应症。长效SSA是一种有效且安全的初级治疗，可在选定患者中长期控制肿瘤生长和症状。© 2023年。作者。

The specific indications of somatostatin analogs (SSAs) in patients with neuroendocrine tumor (NET) emerged over the time. The objective of this review is to summarize and discuss the most relevant data concerning long-acting SSAs in NET.A narrative review was performed including publications focusing on therapy with the long-acting octreotide, lanreotide, and pasireotide in patients with NET.Long-acting SSAs confirm to be a manageable and widely used tool in patients with NET. Both long-acting octreotide and lanreotide are safe as the short-acting formulations, while patient compliance and adherence is further improved. Together with some randomized phase-3 trials, many retrospective and prospective studies have been performed in the last 20 years revealing a variable but substantial impact on progression free survival, not only in gastroenteropancreatic but also in lung and unknown primary NETs. The most frequent tumor response to SSAs is stable disease, but an objective response can be observed, more frequently by using high-dose schedules and in MEN1-related pancreatic NETs. Low tumor burden, low tumor grade (G1 and low G2), good performance status and use as first-line therapy are the main predictive factors to SSAs in NET patients. Pasireotide has been evaluated in few studies. This compound remains a promising SSA and would deserve to be further evaluated as a potential additional indication in NET therapy.Long-acting SSAs are an effective and safe initial therapy of patients with well differentiated NET, allowing tumor growth as well as symptoms control for long-time in selected patients.© 2023. The Author(s).